Araştırma Makalesi
BibTex RIS Kaynak Göster

Yıl 2022, Cilt: 26 Sayı: 6, 1814 - 1824, 28.06.2025

Manohar Babu Sitty Vineela Chadalavada

https://doi.org/10.29228/jrp.272
Cited By: 1

Öz

Kaynakça

  • [1] Shahpiri Z, Bahramsoltani R, Farzaei MH, Farzaei F, Rahimi R. Phytochemicals as future drugs for Parkinson’s disease: a comprehensive review. Reviews in the Neurosciences. 2016; 27(6): 651–668. [CrossRef]
  • [2] Nag N, Jelinek GA. A narrative review of lifestyle factors associated with Parkinson’s disease risk and progression. Neurodegenerative Diseases. 2019; 19(2): 51–59. [CrossRef]
  • [3] Warren N, O’Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. Journal of Neurology, Neurosurgery & Psychiatry. 2017; 88(12): 1060–1064. [CrossRef]
  • [4] Kumar SS. Application of phytochemicals for the treatment of neurodegenerative diseases. Drug Invention Today. 2018; 10(3). [CrossRef]
  • [5] Zhao X, Zhang M, Li C, Jiang X, Su Y, Zhang Y. Benefits of Vitamins in the Treatment of Parkinson’s Disease. Oxidative Medicine and Cellular Longevity. 2019; 2019. [CrossRef]
  • [6] Kamalpreet Kaura NK, Sharmaa N. Phytochemicals as future drugs for Parkinson’s disease: a review. Plant Archives. 2021; 21(1): 2338–2349. [CrossRef]
  • [7] Vasudeva P. Origanum majorana L.-phyto-pharmacological review. Ind J Nat Prod. 2015; 6(4): 261–267.
  • [8] Sameul TKG, Suresh Kumar P, Nari Neethu Letha, Sharmila Banu Gani. Preliminary phytochemical screening of different solvent extract of leaves and stems of Commelina benghalensis L. (Family: Commelinaceae). International Journal of Pharmaceutical, Chemical and Biological Science. 2016; 6(1): 103–107.
  • [9] Kumar CS, Loh WS, Ooi CW, Quah CK, Fun HK. Structural correlation of some heterocyclic chalcone analogues and evaluation of their antioxidant potential. Molecules. 2013; 18(10): 11996–12011. [CrossRef]
  • [10] Forno. Neuropathology of P.D. Journal of Neuropathology and Experimental Neurology. 1996; 55: 259–272. [CrossRef]
  • [11] Wagel M, et al. Physical therapy of PD. Journal of Neurosciences. 2008; 23: 191–193.
  • [12] Deacon RM. Measuring motor coordination in mice. JoVE (Journal of Visualized Experiments). 2013; 29(75): e2609. [CrossRef]
  • [13] Gheitasi I, Motaghi N, Sadeghi H, Moslemi Z, Eftekhari M, et al. Antioxidant and anti-inflammatory effects of Origanum majorana L. methanolic extract on bile duct ligation in male rats. Evid Based Complement Alternat Med. 2021; 2021: 9927196. [CrossRef]
  • [14] Postu PA, Gorgan DL, Cioanca O, Russ M, Mikkat S, Glocker MO, et al. Memory-enhancing effects of Origanum majorana essential oil in an Alzheimer's amyloid beta1-42 rat model: a molecular and behavioral study. Antioxidants (Basel). 2020; 9(10): 919. [CrossRef]
  • [15] Hossain MB, Camphuis G, Aguiló-Aguayo I, Gangopadhyay N, Rai DK. Antioxidant activity guided separation of major polyphenols of marjoram (Origanum majorana L.) using flash chromatography and their identification by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Sep Sci. 2014; 37(22): 3205–3213. [CrossRef]
  • [16] Amaghnouje A, Mechchate H, Es-safi I, Alotaibi AA, Noman OM, et al. Anxiolytic, antidepressant-like properties and impact on the memory of the hydro-ethanolic extract of Origanum majorana L. on mice. Applied Sciences. 2020; 10(23): 8420. [CrossRef]
  • [17] Houghton PJ, Howes MJ. Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease. Neurosignals. 2005; 14(1–2): 6–22. [CrossRef]
  • [18] Sheidaei H. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT1A receptors. DARU: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2010; 18(1): 41. [CrossRef]
  • [19] Barroca NC, Guarda MD, da Silva NT, Colombo AC, Reimer AE, Brandão ML, de Oliveira AR. Influence of aversive stimulation on haloperidol-induced catalepsy in rats. Behavioural Pharmacology. 2019; 30(2): 229–238. [CrossRef]
  • [20] Kumari N, Agrawal S, Kumari R, Sharma D, Luthra PM. Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo[4,5-d]pyrimidin-6(7H)-yl) urea) in 6-OHDA induced rodent model of hemiparkinson’s disease. Neuroscience Letters. 2018; 675: 74–82. [CrossRef]

Anti-Parkinson's activity and in vitro antioxidant activity of Origanum majorana plant extract

Yıl 2022, Cilt: 26 Sayı: 6, 1814 - 1824, 28.06.2025

Manohar Babu Sitty Vineela Chadalavada

https://doi.org/10.29228/jrp.272
Cited By: 1

Öz

Neurodegenerative diseases are increasing worldwide, and new drugs to treat them effectively with fewer side effects are in high demand today. Treatments available for these diseases are associated with significant side effects in the long term. Therefore, finding a therapy that inhibits disease progression with fewer side effects is crucial. Origanum majorana commonly called sweet marjoram was reported to have a wide range of health benefits particularly in treating neurological diseases. In this context, the leaf extract of Origanum majorana was evaluated for its antioxidant, antiparkinson’s and neuroprotective properties. The antioxidant property was assessed by two in-vitro methods, nitric oxide radical scavenging assay and phosphomolybdenum assay. The antiparkinson’s property was assessed in haloperidol-induced Parkinson's disease in mice using the catalepsy bar test and rotarod test. The results of this study show that Origanum Majorana has a powerful antioxidant property that can protect neurons from haloperidol-induced cognitive and motor impairments by reducing oxidation.

Anahtar Kelimeler

Neurodegenerative diseases Origanum majorana Parkinson antioxidant and neuroprotective properties

Kaynakça

  • [1] Shahpiri Z, Bahramsoltani R, Farzaei MH, Farzaei F, Rahimi R. Phytochemicals as future drugs for Parkinson’s disease: a comprehensive review. Reviews in the Neurosciences. 2016; 27(6): 651–668. [CrossRef]
  • [2] Nag N, Jelinek GA. A narrative review of lifestyle factors associated with Parkinson’s disease risk and progression. Neurodegenerative Diseases. 2019; 19(2): 51–59. [CrossRef]
  • [3] Warren N, O’Gorman C, Lehn A, Siskind D. Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases. Journal of Neurology, Neurosurgery & Psychiatry. 2017; 88(12): 1060–1064. [CrossRef]
  • [4] Kumar SS. Application of phytochemicals for the treatment of neurodegenerative diseases. Drug Invention Today. 2018; 10(3). [CrossRef]
  • [5] Zhao X, Zhang M, Li C, Jiang X, Su Y, Zhang Y. Benefits of Vitamins in the Treatment of Parkinson’s Disease. Oxidative Medicine and Cellular Longevity. 2019; 2019. [CrossRef]
  • [6] Kamalpreet Kaura NK, Sharmaa N. Phytochemicals as future drugs for Parkinson’s disease: a review. Plant Archives. 2021; 21(1): 2338–2349. [CrossRef]
  • [7] Vasudeva P. Origanum majorana L.-phyto-pharmacological review. Ind J Nat Prod. 2015; 6(4): 261–267.
  • [8] Sameul TKG, Suresh Kumar P, Nari Neethu Letha, Sharmila Banu Gani. Preliminary phytochemical screening of different solvent extract of leaves and stems of Commelina benghalensis L. (Family: Commelinaceae). International Journal of Pharmaceutical, Chemical and Biological Science. 2016; 6(1): 103–107.
  • [9] Kumar CS, Loh WS, Ooi CW, Quah CK, Fun HK. Structural correlation of some heterocyclic chalcone analogues and evaluation of their antioxidant potential. Molecules. 2013; 18(10): 11996–12011. [CrossRef]
  • [10] Forno. Neuropathology of P.D. Journal of Neuropathology and Experimental Neurology. 1996; 55: 259–272. [CrossRef]
  • [11] Wagel M, et al. Physical therapy of PD. Journal of Neurosciences. 2008; 23: 191–193.
  • [12] Deacon RM. Measuring motor coordination in mice. JoVE (Journal of Visualized Experiments). 2013; 29(75): e2609. [CrossRef]
  • [13] Gheitasi I, Motaghi N, Sadeghi H, Moslemi Z, Eftekhari M, et al. Antioxidant and anti-inflammatory effects of Origanum majorana L. methanolic extract on bile duct ligation in male rats. Evid Based Complement Alternat Med. 2021; 2021: 9927196. [CrossRef]
  • [14] Postu PA, Gorgan DL, Cioanca O, Russ M, Mikkat S, Glocker MO, et al. Memory-enhancing effects of Origanum majorana essential oil in an Alzheimer's amyloid beta1-42 rat model: a molecular and behavioral study. Antioxidants (Basel). 2020; 9(10): 919. [CrossRef]
  • [15] Hossain MB, Camphuis G, Aguiló-Aguayo I, Gangopadhyay N, Rai DK. Antioxidant activity guided separation of major polyphenols of marjoram (Origanum majorana L.) using flash chromatography and their identification by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Sep Sci. 2014; 37(22): 3205–3213. [CrossRef]
  • [16] Amaghnouje A, Mechchate H, Es-safi I, Alotaibi AA, Noman OM, et al. Anxiolytic, antidepressant-like properties and impact on the memory of the hydro-ethanolic extract of Origanum majorana L. on mice. Applied Sciences. 2020; 10(23): 8420. [CrossRef]
  • [17] Houghton PJ, Howes MJ. Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease. Neurosignals. 2005; 14(1–2): 6–22. [CrossRef]
  • [18] Sheidaei H. Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT1A receptors. DARU: Journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2010; 18(1): 41. [CrossRef]
  • [19] Barroca NC, Guarda MD, da Silva NT, Colombo AC, Reimer AE, Brandão ML, de Oliveira AR. Influence of aversive stimulation on haloperidol-induced catalepsy in rats. Behavioural Pharmacology. 2019; 30(2): 229–238. [CrossRef]
  • [20] Kumari N, Agrawal S, Kumari R, Sharma D, Luthra PM. Neuroprotective effect of IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo[4,5-d]pyrimidin-6(7H)-yl) urea) in 6-OHDA induced rodent model of hemiparkinson’s disease. Neuroscience Letters. 2018; 675: 74–82. [CrossRef]
Toplam 20 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Farmakognozi
Bölüm Articles
Yazarlar

Manohar Babu Sitty

Vineela Chadalavada

Yayımlanma Tarihi 28 Haziran 2025
Yayımlandığı Sayı Yıl 2022 Cilt: 26 Sayı: 6

Kaynak Göster

APA Sitty, M. B., & Chadalavada, V. (2025). Anti-Parkinson’s activity and in vitro antioxidant activity of Origanum majorana plant extract. Journal of Research in Pharmacy, 26(6), 1814-1824. https://doi.org/10.29228/jrp.272
AMA Sitty MB, Chadalavada V. Anti-Parkinson’s activity and in vitro antioxidant activity of Origanum majorana plant extract. J. Res. Pharm. Haziran 2025;26(6):1814-1824. doi:10.29228/jrp.272
Chicago Sitty, Manohar Babu, ve Vineela Chadalavada. “Anti-Parkinson’s Activity and in Vitro Antioxidant Activity of Origanum Majorana Plant Extract”. Journal of Research in Pharmacy 26, sy. 6 (Haziran 2025): 1814-24. https://doi.org/10.29228/jrp.272.
EndNote Sitty MB, Chadalavada V (01 Haziran 2025) Anti-Parkinson’s activity and in vitro antioxidant activity of Origanum majorana plant extract. Journal of Research in Pharmacy 26 6 1814–1824.
IEEE M. B. Sitty ve V. Chadalavada, “Anti-Parkinson’s activity and in vitro antioxidant activity of Origanum majorana plant extract”, J. Res. Pharm., c. 26, sy. 6, ss. 1814–1824, 2025, doi: 10.29228/jrp.272.
ISNAD Sitty, Manohar Babu - Chadalavada, Vineela. “Anti-Parkinson’s Activity and in Vitro Antioxidant Activity of Origanum Majorana Plant Extract”. Journal of Research in Pharmacy 26/6 (Haziran 2025), 1814-1824. https://doi.org/10.29228/jrp.272.
JAMA Sitty MB, Chadalavada V. Anti-Parkinson’s activity and in vitro antioxidant activity of Origanum majorana plant extract. J. Res. Pharm. 2025;26:1814–1824.
MLA Sitty, Manohar Babu ve Vineela Chadalavada. “Anti-Parkinson’s Activity and in Vitro Antioxidant Activity of Origanum Majorana Plant Extract”. Journal of Research in Pharmacy, c. 26, sy. 6, 2025, ss. 1814-2, doi:10.29228/jrp.272.
Vancouver Sitty MB, Chadalavada V. Anti-Parkinson’s activity and in vitro antioxidant activity of Origanum majorana plant extract. J. Res. Pharm. 2025;26(6):1814-2.

Cited By

Origanum majorana L. protects against neuroinflammation-mediated cognitive impairment: a phyto-pharmacological study
BMC Complementary Medicine and Therapies
https://doi.org/10.1186/s12906-023-03994-x